Figure S5


A
CIRI Model Predictions
(CLL-IPI + Interim MRD)
Absolute Benefit of FCR
(PFS at 36 Months)
Threshold
Low Risk (Below Threshold)
High Risk (Above Threshold)
Selected Predictive Threshold
B
CIRI Identifies Groups Who
Preferentially Benefit from FCR
Absolute Benefit of FCR
(PFS at 36 Months)
CIRI threshold
Low Risk (Below Threshold)
High Risk (Above Threshold)
C
Predicted vs Measured Benefit of
FCR Across All Thresholds
Measured Benefit of FCR
(PFS at 36 Months)
Predicted Benefit of FCR
(PFS @ 36mo)
Low Risk (Below Threshold)
High Risk (Above Threshold)
D
GSE22226
GSE109710
Diagnosis
Neoadjuvant Therapy
Pathologic Response
Neoadjuvant Therapy
Pathologic Response Assessment
pCR Personalized Adjuvant Therapy
Path CR
No Path CR
Compare Benefit of Trastuzumab + Pertuzumab vs Standard Therapy (S5N)
DFS36
Compare Benefit of Trastuzumab + Pertuzumab vs Standard Therapy (S5O)
G
GSE22226
GSE109710
Stage
Grade
Receptors
Diagnosis
Neoadjuvant Therapy
Pathologic Response
Neoadjuvant Therapy
CIRI Risk Assessment
CIRI Personalized Adjuvant Therapy
Low Risk
High Risk
Compare Benefit of Trastuzumab + Pertuzumab vs Standard Therapy (S5Q)
DFS36
Compare Benefit of Trastuzumab + Pertuzumab vs Standard Therapy (S5R)
E
Pathological CR
Probability of DFS
Months
T+P (n=101)
Standard (n=26)
P=0.2114
F
No Pathological CR
Probability of PFS
Months
T+P (n=61)
Standard (n=13)
P=0.1000
H
CIRI Low Risk
(<15% Predicted Event-Rate by 36 Months)
Probability of DFS
Months
T+P (n=89)
Standard (n=24)
P=0.9274
I
CIRI High Risk
(>15% Predicted Event-Rate by 36 Months)
Probability of DFS
Months
T+P (n=73)
Standard (n=15)
P=0.0059
J
CIRI Model Predictions
(Stage+Grade+Receptors+Path Response)
Absolute Benefit of T+P
(DFS at 36mo)
Threshold
Low Risk (Below Threshold)
High Risk (Above Threshold)
Selected Predictive Threshold
K
CIRI Identifies Groups Who
Preferentially Benefit from
Trastuzumab + Pertuzumab
Absolute Benefit of T+P
(DFS at 36mo)
Threshold
Low Risk (Below Threshold)
High Risk (Above Threshold)
L
Predicted vs Measured Benefit of
Trastuzumab+Pertuzumab Across All Thresholds
Measured Benefit of T+P
(DFS at 36mo)
Predicted Benefit of T+P
(DFS @ 36mo)
Low Risk (Below Threshold)
High Risk (Above Threshold)